View Older Stories View More Recent Stories
-
Novartis Said To Near Deal $70-per-share-plus Deal For Avidity Biosciences (RNA) - Bloomberg
-
Novartis reports sustained benefit from Kisqali in breast cancer trial
-
Novartis receives positive EMA opinion for Scemblix CML treatment
-
Novartis receives FDA approval for oral CSU treatment Rhapsido
-
M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
-
EU will still have 15% pharma tariff, not 100% - Bloomberg
-
Novartis presents Kesimpta data showing disease activity reduction in MS patients
-
Monte Rosa surges premarket on Novartis collaboration deal
-
Goldman Sachs Downgrades Novartis (NOVN:SW) (NVS) to Sell
-
Argo Biopharma signs $160 million deal with Novartis for heart drugs
-
Novartis (NOVN:SW) (NVS) PT Raised to CHF120 at Deutsche Bank
-
Morgan Stanley Upgrades Novartis (NVS) to Equalweight
-
Novartis (NVS) Made A Takeover Approach Avidity Biosciences (RNA) - FT
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
Novartis (NVS) Tops Q2 EPS by 7c; raises FY guidance
-
Novartis (NVS) Failed To Prove Infringement At Delaware Bench Trial - Bloomberg
-
Novartis (NVS) provides update on Phase III GCAptAIN study of Cosentyx in giant cell arteritis
-
Several Forms Of Generic Ritalin Fail To Work Correctly: Study - Bloomberg
-
Wegovy Use Up 50% Among Us Teens - Reuters
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), Comments on Novo's Wegovy Price Promo: 'We see this as another potential headwind for HIMS
-
Incyte (INCY) and Novartis (NVS) entered into settlement agreement
-
WHO to Back Use of Weight-loss Drugs for Adults Globally, Raises Cost Issue - Reuters
-
Regulus Therapeutics (RGLS) to be Acquired by Novartis (NVS) for $7 Per Share
-
Novartis (NVS) Reports Q1 EPS of $2.28; offers outlook
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
Novartis (NVS) May 110 straddle priced into quarter results
-
BNP Paribas Exane Starts Novartis (NOVN:SW) (NVS) at Outperform
-
Novartis (NVS) plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years
-
Pharma stocks slide after Trump signals tariffs on sector
-
Novartis (NOVN:SW) (NVS) PT Raised to CHF115 at Deutsche Bank
-
Novartis receives third FDA approval for oral Fabhalta
-
Novartis named corporate pharmaceutical partner of the NFL
-
Increasing unusual option volume: AMKR UMC IVV PTEN TER NVS INFY VSCO
-
Novartis Holder Emasan Ag Offering About 26.5m Shares: Terms - Bloomberg
-
UBS Downgrades Novartis (NOVN:SW) (NVS) to Neutral
-
Morgan Stanley Starts Novartis (NOVN:SW) (NVS) at Underweight
-
Deutsche Bank Upgrades Novartis (NOVN:SW) (NVS) to Buy
-
Novartis (NVS) Tops Q4 EPS by 16c; offers guidance
-
Novartis (NVS) call put ratio 1 call to 1.7 puts with a focus on February 95 puts into quarter results
-
Novartis (NVS) call put ratio 1 call to 15.6 puts with a focus on February 95 puts
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
BioAge Labs (BIOA) Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
HSBC Downgrades Novartis (NOVN:SW) (NVS) to Reduce
-
JPMorgan Reiterates Overweight Rating on PTC Therapeutics (PTCT)
-
PTC Therapeutics (PTCT) Enters into a Global License and Collaboration Agreement with Novartis (NVS) for PTC518 Huntington's Disease Program
-
BMO Capital Reiterates Outperform Rating on Novartis (NVS)
-
Novartis (NVS) PT Raised to $120 at BMO Capital
-
Novartis (NVS) Tops Q3 EPS by 12c
-
Novartis (NVS) call put ratio 5 calls to 1 put into quarter results
